Suppr超能文献

经导管同期双瓣膜置换术(二尖瓣和三尖瓣):一例病例报告

Simultaneous transcatheter dual valve replacement (mitral and tricuspid valves): a case report.

作者信息

Garg Piyush, Chouhan Nagendra, Wander Gagandeep S, Chandra Praveen, Kashyap Rahul

机构信息

Department of Cardiology, Medanta-The Medicity, CH Baktawar Singh Rd, Islampur Colony, Sector 38, Gurugram, Haryana 122001, India.

Critical Care Medicine, Mayo Clinic, 201 W. Center St. Rochester, MN 55902, USA.

出版信息

Eur Heart J Case Rep. 2023 Aug 1;7(8):ytad344. doi: 10.1093/ehjcr/ytad344. eCollection 2023 Aug.

Abstract

BACKGROUND

Structural valve dysfunction in bioprosthetic heart valves necessitates redo replacement procedure that are associated with high mortality and morbidity. The transcatheter valve-in-valve (VIV) approach has emerged as a preferred option for patients requiring redo procedures due to structural valve degeneration. We report from India the first case of the simultaneous transcatheter dual VIV implantation (mitral valve and tricuspid valves) in a high-surgical-risk patient.

CASE SUMMARY

A 57-year-old female was presented with a history of rheumatic heart disease, post-mitral valve as well as tricuspid valve replacement (perimount 33 mm) 11 years back. Bioprosthetic heart valve was chosen probably due to limited life expectancy and compliance issues with monitoring of international normalised ratio (INR). She now presented with progressive dyspnoea, oedema, and palpitations (New York Heart Association Class III) for the last 6 months. The patient was scheduled for transcatheter dual valve replacement simultaneously. The procedure was successful with a favourable outcome, short hospital stays, and early recovery.

DISCUSSION

This is the first case of simultaneous transcatheter dual valve replacement reported from India, which is fluoroscopically guided and supported by TEE. It is a valuable and considerable option for patients with failing bioprosthesis valves who are at increased peri-operative risk.

摘要

背景

生物人工心脏瓣膜的结构功能障碍需要再次进行置换手术,而这种手术与高死亡率和高发病率相关。经导管瓣膜内瓣膜(VIV)方法已成为因结构瓣膜退变而需要再次手术的患者的首选方案。我们报道了印度首例在高手术风险患者中同时经导管进行双VIV植入(二尖瓣和三尖瓣)的病例。

病例摘要

一名57岁女性有风湿性心脏病病史,11年前接受了二尖瓣及三尖瓣置换术(使用33毫米的Perimount瓣膜)。选择生物人工心脏瓣膜可能是由于预期寿命有限以及国际标准化比值(INR)监测的依从性问题。她在过去6个月出现进行性呼吸困难、水肿和心悸(纽约心脏协会III级)。该患者计划同时进行经导管双瓣膜置换术。手术成功,结果良好,住院时间短,恢复早。

讨论

这是印度报道的首例在荧光镜引导下并由经食管超声心动图(TEE)支持的同时经导管双瓣膜置换病例。对于生物人工瓣膜功能衰竭且围手术期风险增加的患者来说,这是一个有价值且值得考虑的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85b2/10401318/9caf84961535/ytad344f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验